BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815-820. [PMID: 8596547 DOI: 10.1056/nejm199603283341302] [Cited by in Crossref: 778] [Cited by in F6Publishing: 120] [Article Influence: 29.9] [Reference Citation Analysis]
Number Citing Articles
1 Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, Guichard S, Ducerf C, Baulieux J, Zoulim F. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut. 2003;52:283-287. [PMID: 12524414 DOI: 10.1136/gut.52.2.283] [Cited by in Crossref: 131] [Cited by in F6Publishing: 110] [Article Influence: 6.9] [Reference Citation Analysis]
2 Alsatie M, Chalasani N, Kwo PY. Management of hepatitis C infection after liver transplantation. Drugs 2007;67:871-85. [PMID: 17428105 DOI: 10.2165/00003495-200767060-00004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
3 Gitto S, Belli LS, Vukotic R, Lorenzini S, Airoldi A, Cicero AFG, Vangeli M, Brodosi L, Panno AM, Di Donato R, Cescon M, Grazi GL, De Carlis L, Pinna AD, Bernardi M, Andreone P. Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation. World J Gastroenterol 2015; 21(13): 3912-3920 [PMID: 25852276 DOI: 10.3748/wjg.v21.i13.3912] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
4 Pascher A, Nebrig M, Neuhaus P. Irreversible liver failure: treatment by transplantation: part 3 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:167-73. [PMID: 23533548 DOI: 10.3238/arztebl.2013.0167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
5 Akamatsu N, Sugawara Y. Living-donor liver transplantation and hepatitis C. HPB Surg 2013;2013:985972. [PMID: 23401640 DOI: 10.1155/2013/985972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 Layden JE, Cotler SJ, Grim SA, Fischer MJ, Lucey MR, Clark NM. Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation. 2012;93:444-449. [PMID: 22277982 DOI: 10.1097/tp.0b013e3182406a94] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Koike K, Takaki A, Yagi T, Iwasaki Y, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M, Miyake Y, Ikeda F, Shiraha H, Fujiwara T, Yamamoto K. Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors. Transplantation 2015;99:1447-54. [PMID: 25675203 DOI: 10.1097/TP.0000000000000572] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Nagata I, Tzampouras N, Chokshi S, Naoumov NV, Cheeseman P, Smith HM, Baker AJ, Williams R, Mieli-Vergani G. Hepatitis GB virus-C/hepatitis G virus infection in liver disease. Arch Dis Child 1997;77:223-6. [PMID: 9370900 DOI: 10.1136/adc.77.3.223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
9 Wong-Staal F, Syder AJ, McKelvy JF. Targeting HCV entry for development of therapeutics. Viruses 2010;2:1718-33. [PMID: 21994703 DOI: 10.3390/v2081718] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
10 Nguyen NH, Yee BE, Chang C, Jin M, Lutchman G, Lim JK, Nguyen MH. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ Open Gastroenterol 2016;3:e000066. [PMID: 26966549 DOI: 10.1136/bmjgast-2015-000066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
11 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
12 Carbone M, Neuberger J. Liver transplantation for hepatitis C and alcoholic liver disease. J Transplant. 2010;2010:893893. [PMID: 21209701 DOI: 10.1155/2010/893893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
13 Benten D, Staufer K, Sterneck M. Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner. Nat Clin Pract Gastroenterol Hepatol 2009;6:23-36. [PMID: 19029996 DOI: 10.1038/ncpgasthep1312] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
14 Singal AK, Salameh H, Singal A, Jampana SC, Freeman DH, Anderson KE, Brunder D. Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther 2013; 4(2): 16-22 [PMID: 23667769 DOI: 10.4292/wjgpt.v4.i2.16] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wietzke-Braun P, Braun F, Sattler B, Ramadori G, Ringe B. Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis c virus related cirrhosis. World J Gastroenterol 2004; 10(15): 2213-2217 [PMID: 15259068 DOI: 10.3748/wjg.v10.i15.2213] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
16 Watt KD, Burak K, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network. Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol 2006;20:725-34. [PMID: 17111055 DOI: 10.1155/2006/238218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Guido M, Fagiuoli S, Tessari G, Burra P, Leandro G, Boccagni P, Cillo U, Naccarato R, Rugge M. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 2002;50:697-700. [PMID: 11950819 DOI: 10.1136/gut.50.5.697] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
18 Vargas HE, Rakela J. Impact of hepatitis B and hepatitis C on solid organ transplantation: . Current Opinion in Organ Transplantation 2002;7:325-31. [DOI: 10.1097/00075200-200212000-00005] [Reference Citation Analysis]
19 Gehrau R, Mas V, Archer K, Maluf D. Biomarkers of disease differentiation: HCV recurrence versus acute cellular rejection. Fibrogenesis Tissue Repair 2012;5:S11. [PMID: 23259646 DOI: 10.1186/1755-1536-5-S1-S11] [Reference Citation Analysis]
20 Gehrau R, Maluf D, Archer K, Stravitz R, Suh J, Le N, Mas V. Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mol Med. 2011;17:824-833. [PMID: 21519635 DOI: 10.2119/molmed.2011.00072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
21 Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, Dusheiko G, Davidson B, Rolles K, Burroughs AK. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut. 1999;45:427-434. [PMID: 10446114 DOI: 10.1136/gut.45.3.427] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 2.2] [Reference Citation Analysis]
22 Dhar S, Omran L, Bacon BR, Solomon H, Di Bisceglie AM. Liver transplantation in patients with chronic hepatitis C and alcoholism. Dig Dis Sci 1999;44:2003-7. [PMID: 10548350 DOI: 10.1023/a:1026614116808] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
23 Paik SW, Tan HP, Klein AS, Boitnott JK, Thuluvath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci. 2002;47:450-455. [PMID: 11855567 DOI: 10.1023/a: 1013759230800] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835-842. [PMID: 22147444 DOI: 10.1002/art.34322] [Cited by in Crossref: 154] [Cited by in F6Publishing: 119] [Article Influence: 15.4] [Reference Citation Analysis]
25 Prince MI, Hudson M. Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortages. Postgrad Med J 2002;78:135-41. [PMID: 11884694 DOI: 10.1136/pmj.78.917.135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
26 Mudawi H, Helmy A, Kamel Y, Al Saghier M, Al Sofayan M, Al Sebayel M, Khalaf H, Al Bahili H, Al Shiek Y, Alawi K, Aljedai A, Mohamed H, Al Hamoudi W, Abdo A. Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation: natural history and predictors of outcome. Ann Saudi Med 2009;29:91-7. [PMID: 19318754 DOI: 10.4103/0256-4947.51796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
27 Gayowski T, Singh N, Marino IR, Vargas H, Wagener M, Wannstedt C, Morelli F, Laskus T, Fung JJ, Rakela J. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation. 1997;64:422-426. [PMID: 9275107 DOI: 10.1097/00007890-199708150-00009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 2.7] [Reference Citation Analysis]
28 Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut. 1998;42:744-749. [PMID: 9659174 DOI: 10.1136/gut.42.5.744] [Cited by in Crossref: 104] [Cited by in F6Publishing: 80] [Article Influence: 4.3] [Reference Citation Analysis]
29 Ho CM, Hu RH, Lee PH. Perspective of antiviral therapeutics for hepatitis C after liver transplantation. World J Pharmacol 2014; 3(4): 193-198 [DOI: 10.5497/wjp.v3.i4.193] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Sheen V, Nguyen H, Jimenez M, Agopian V, Vangala S, Elashoff D, Saab S. Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. J Clin Transl Hepatol 2016;4:20-5. [PMID: 27047768 DOI: 10.14218/JCTH.2015.00034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Sawyer RG, Pelletier SJ, Spencer CE, Pruett TL, Isaacs RB. Increased late hepatic artery thrombosis rate and decreased graft survival after liver transplants with zero cross-reactive group mismatches. Liver Transpl 2000;6:229-36. [PMID: 10719025 DOI: 10.1002/lt.500060202] [Reference Citation Analysis]
32 Sheiner PA, Florman SS, Emre S, Fishbein T, Schwartz ME, Miller CM, Boros P. Recurrence of hepatitis C after liver transplantation is associated with increased systemic IL-10 levels. Mediators Inflamm 2001;10:37-41. [PMID: 11324903 DOI: 10.1080/09629350124104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
33 Zanaga LP, Vigani AG, Angerami RN, Giorgetti A, Escanhoela CA, Ataíde EC, Boin IF, Stucchi RS. Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation. Braz J Med Biol Res 2017;50:e5540. [PMID: 28076451 DOI: 10.1590/1414-431X20165540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, Starzl TE, Fung JJ, Demetris AJ. Liver transplantation for alcoholic cirrhosis: Long term follow-up and impact of disease recurrence. Transplantation. 2001;72:619-626. [PMID: 11544420 DOI: 10.1097/00007890-200108270-00010] [Cited by in Crossref: 133] [Cited by in F6Publishing: 107] [Article Influence: 6.3] [Reference Citation Analysis]
35 Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, Abu-Elmagd K, Marsh W, Madariaga J, Mazariegos G, Geller D, Bonham CA, Gayowski T, Cacciarelli T, Fontes P, Starzl TE, Fung JJ. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232:490-500. [PMID: 10998647 DOI: 10.1097/00000658-200010000-00004] [Cited by in Crossref: 386] [Cited by in F6Publishing: 318] [Article Influence: 17.5] [Reference Citation Analysis]
36 Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog. 2012;8:e1002895. [PMID: 22952447 DOI: 10.1371/journal.ppat.1002895] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 11.5] [Reference Citation Analysis]
37 Murase J, Kubo S, Nishiguchi S, Hirohashi K, Shuto T, Ikebe T, Kinoshita H. Correlation of clinicopathologic features of resected hepatocellular carcinoma with hepatitis C virus genotype. Jpn J Cancer Res. 1999;90:1293-1300. [PMID: 10665645 DOI: 10.1111/j.1349-7006.1999.tb00711.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
38 Akamatsu N, Sugawara Y. Liver transplantation and hepatitis C. Int J Hepatol 2012;2012:686135. [PMID: 22900194 DOI: 10.1155/2012/686135] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
39 Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 2016;22:287-97. [PMID: 26437376 DOI: 10.1002/lt.24349] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
40 Berenguer M, Wright TL. Hepatitis C and liver transplantation. Gut. 1999;45:159-163. [PMID: 10403720 DOI: 10.1136/gut.45.2.159] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 1.1] [Reference Citation Analysis]
41 Walsh K, Alexander GJ. Update on chronic viral hepatitis. Postgrad Med J 2001;77:498-505. [PMID: 11470928 DOI: 10.1136/pmj.77.910.498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
42 Al-Hamoudi W, Mohamed H, Abaalkhail F, Kamel Y, Al-Masri N, Allam N, Alqahtani S, Al-Sofayan M, Khalaf H, Al-Sebayel M, Al-Jedai A, Abdo A. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Dig Dis Sci 2011;56:1848-52. [PMID: 21221800 DOI: 10.1007/s10620-010-1526-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
43 Kim H, Lee KW, Yi NJ, Lee HW, Choi Y, Suh SW, Jeong J, Suh KS. Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation. J Korean Med Sci 2015;30:1577-83. [PMID: 26539000 DOI: 10.3346/jkms.2015.30.11.1577] [Reference Citation Analysis]
44 Meriden Z, Forde KA, Pasha TL, Hui JJ, Reddy KR, Furth EE, Wells RG. Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010;8:289-296, 296.e1-8. [PMID: 19913638 DOI: 10.1016/j.cgh.2009.10.034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
45 Varma V, Webb K, Mirza DF. Liver transplantation for alcoholic liver disease. World J Gastroenterol 2010; 16(35): 4377-4393 [PMID: 20845504 DOI: 10.3748/wjg.v16.i35.4377] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
46 Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. Semin Immunopathol. 2013;35:101-110. [PMID: 22829333 DOI: 10.1007/s00281-012-0329-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
47 Siciliano M, Parlati L, Maldarelli F, Rossi M, Ginanni Corradini S. Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012; 3(4): 49-61 [PMID: 22966483 DOI: 10.4292/wjgpt.v3.i4.49] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
48 Li H, Sullivan DG, Feuerborn N, McArdle S, Bekele K, Pal S, Yeh M, Carithers RL, Perkins JD, Gretch DR. Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation. Virology 2010;402:248-55. [PMID: 20400171 DOI: 10.1016/j.virol.2010.03.040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
49 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
50 Balagopal A, Ray SC, De Oca RM, Sutcliffe CG, Vivekanandan P, Higgins Y, Mehta SH, Moore RD, Sulkowski MS, Thomas DL, Torbenson MS. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS. 2009;23:2397-2404. [PMID: 19773633 DOI: 10.1097/qad.0b013e3283324344] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
51 Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int 2016;10:749-61. [PMID: 27337961 DOI: 10.1007/s12072-016-9744-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
52 Nellore A, Fishman JA. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis. 2011;52:369-377. [PMID: 21217184 DOI: 10.1093/cid/ciq156] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
53 Yoon JH, Lee JY, Woo HS, Yu MH, Lee ES, Joo I, Lee KB, Yi NJ, Lee YJ, Han JK. Shear wave elastography in the evaluation of rejection or recurrent hepatitis after liver transplantation. Eur Radiol. 2013;23:1729-1737. [PMID: 23300037 DOI: 10.1007/s00330-012-2748-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
54 Boillot O, Dumortier J. Immunosuppression in HCV-positive liver transplant recipients: Pandora's box? Liver Transpl 2007;13:1500-2. [PMID: 17969204 DOI: 10.1002/lt.21224] [Reference Citation Analysis]
55 Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol 2020; 12(9): 628-640 [PMID: 33033569 DOI: 10.4254/wjh.v12.i9.628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Lipman MM, Cotler SJ. Antiviral Therapy for Hepatitis C. Curr Treat Options Gastroenterol 2003;6:445-53. [PMID: 14585233 DOI: 10.1007/s11938-003-0046-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
57 Vogten JM, Drixler TA, Te Velde EA, Schipper ME, Van Vroonhoven TJ, Voest EE, Borel Rinkes IH. Angiostatin inhibitsexperimental liver fibrosis in mice. Int J Colorectal Dis. 2004;19:387-394. [PMID: 14716496 DOI: 10.1007/s00384-003-0562-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
58 Lim JK, Wooten D, Siegel R, Cheung RC. Amantadine in treatment of chronic hepatitis C virus infection? J Viral Hepat 2005;12:445-55. [PMID: 16108758 DOI: 10.1111/j.1365-2893.2005.00622.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
59 Cameron AM, Ghobrial RM, Hiatt JR, Carmody IC, Gordon SA, Farmer DG, Yersiz H, Zimmerman MA, Durazo F, Han SH, Saab S, Gornbein J, Busuttil RW. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006;244:563-71. [PMID: 16998365 DOI: 10.1097/01.sla.0000237648.90600.e9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
60 Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, Wiselka M, Norris S. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52:1035-40. [PMID: 12801963 DOI: 10.1136/gut.52.7.1035] [Cited by in Crossref: 180] [Cited by in F6Publishing: 170] [Article Influence: 9.5] [Reference Citation Analysis]
61 Carbone M, Lenci I, Baiocchi L. Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther 2012; 3(4): 36-48 [PMID: 22966482 DOI: 10.4292/wjgpt.v3.i4.36] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Singh G, Selby R, Genyk Y, Mateo R, Sher L, Jabbour N. Using hepatitis-positive donors for solid organ transplantation: . Current Opinion in Organ Transplantation 2003;8:341-7. [DOI: 10.1097/00075200-200312000-00014] [Reference Citation Analysis]
63 Hanouneh IA, Zein NN, Lopez R, Yerian L, Fung J, Eghtesad B. IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens. Int J Organ Transplant Med. 2010;1:7-14. [PMID: 25013557 DOI: 10.1016/s0016-5085(08)63573-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616 [PMID: 26140081 DOI: 10.4254/wjh.v7.i12.1606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
65 Varma V, Webb K, Mirza DF. Liver transplantation for alcoholic liver disease. World J Gastroenterol 2010;16:4377-93. [PMID: 20845504 DOI: 10.3748/wjg.v16.i35.4377] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Croitoru A, Schiano TD, Schwartz M, Roayaie S, Xu R, Suriawinata A, Fiel MI. De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci. 2006;51:1780-1782. [PMID: 16967310 DOI: 10.1007/s10620-006-9333-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
67 Hashemi N, Araya V, Tufail K, Thummalakunta L, Feyssa E, Azhar A, Niazi M, Ortiz J. An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol 2011; 3(7): 198-204 [PMID: 21866251 DOI: 10.4254/wjh.v3.i7.198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
68 Roy A, Wang C, Li C, Lu L, Torbenson M, Hagedorn CH, Schwarz KB. Phenotypic and genotypic differences between a child with vertically acquired severe hepatitis C liver disease and his mother. J Pediatr Gastroenterol Nutr 2012;54:567-9. [PMID: 21716134 DOI: 10.1097/MPG.0b013e318229d96f] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
69 Al-Hamoudi WK. Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol 2016;22:173-82. [PMID: 27184634 DOI: 10.4103/1319-3767.182453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002;51:248-252. [PMID: 12117889 DOI: 10.1136/gut.51.2.248] [Cited by in Crossref: 229] [Cited by in F6Publishing: 213] [Article Influence: 11.5] [Reference Citation Analysis]
71 Bizollon T, Ahmed SN, Guichard S, Chevallier P, Adham M, Ducerf C, Baulieux J, Trepo C. Anti-hepatitis C virus core IgM antibodies correlate with hepatitis C recurrence and its severity in liver transplant patients. Gut 2000;47:698-702. [PMID: 11034588 DOI: 10.1136/gut.47.5.698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
72 Mutimer D. Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection? Gut 1999;45:475-6. [PMID: 10486345 DOI: 10.1136/gut.45.4.475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
73 Huang JW, Hernandez-Alejandro R, Croome KP, Yan LN, Wu H, Chen ZY, Prasoon P, Zeng Y. Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations. World J Gastroenterol 2011; 17(1): 123-129 [PMID: 21218093 DOI: 10.3748/wjg.v17.i1.123] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
74 Bailly F, Ahmed SN, Pradat P, Trepo C. Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther 2010;8:379-95. [PMID: 20377334 DOI: 10.1586/eri.10.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Cholankeril G, Joseph-Talreja M, Perumpail BJ, Liu A, Yoo ER, Ahmed A, Goel A. Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents. J Clin Transl Hepatol 2017;5:363-7. [PMID: 29226102 DOI: 10.14218/JCTH.2017.00007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
76 Hsu SH, Yeh ML, Wang SN. New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol. 2013;2013:890517. [PMID: 23710205 DOI: 10.1155/2013/890517] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
77 Sharma P, Hosmer A, Appelman H, McKenna B, Jafri MS, Sullivan P, Fontana RJ, Lok AS. Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival. Hepatol Int 2013;7:990-9. [PMID: 25815091 DOI: 10.1007/s12072-013-9436-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
78 Reau N, Kwo PY, Rhee S, Brown RS, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68:1298-1307. [PMID: 29672891 DOI: 10.1002/hep.30046] [Cited by in Crossref: 105] [Cited by in F6Publishing: 87] [Article Influence: 26.3] [Reference Citation Analysis]
79 Kogiso T, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, Egawa H, Yamamoto M, Tokushige K. Spontaneous clearance of HCV accompanying hepatitis after liver transplantation. Clin J Gastroenterol. 2015;8:323-329. [PMID: 26342292 DOI: 10.1007/s12328-015-0602-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Sugawara Y, Makuuchi M. Living donor liver transplantation to patients with hepatitis C virus cirrhosis. World J Gastroenterol 2006; 12(28): 4461-4465 [PMID: 16874855 DOI: 10.3748/wjg.v12.i28.4461] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
81 Pan Q, Tilanus HW, Metselaar HJ, Janssen HL, van der Laan LJ. Virus-drug interactions--molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol. 2012;9:355-362. [PMID: 22508161 DOI: 10.1038/nrgastro.2012.67] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
82 Kelly DA. Hepatitis C infection after blood product transfusion. Arch Dis Child 1996;75:363-5. [PMID: 8957946 DOI: 10.1136/adc.75.5.363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
83 Mueller JL, King LY, Johnson KB, Gao T, Nephew LD, Kothari D, Simpson MA, Zheng H, Wei L, Corey KE, Misdraji J, Lee JH, Lin MV, Gogela NA, Fuchs BC, Tanabe KK, Gordon FD, Curry MP, Chung RT. Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clin Transplant 2016;30:452-60. [PMID: 26854475 DOI: 10.1111/ctr.12710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
84 Paik SW, Tan HP, Klein AS, Boitnott JK, Thuluvath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci 2002;47:450-5. [PMID: 11855567 DOI: 10.1023/a:1013759230800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
85 El Awady MK, Bader El Din NG, Abdel Aziz Riad M, Omran MH, Abdelhafez TH, Elbaz TM, Hunter SS, Dawood RM, Abdel Aziz AO. Predictors of disease recurrence post living donor liver transplantation in end stage chronic HCV patients. Dis Markers 2014;2014:202548. [PMID: 24695489 DOI: 10.1155/2014/202548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
86 Llorens-Revull M, Gregori J, Dopazo C, Rodriguez-Frías F, Garcia-Cehic D, Soria ME, Chen Q, Rando A, Perales C, Esteban JI, Quer J, Bilbao I. Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients. Genes (Basel) 2021;12:1731. [PMID: 34828337 DOI: 10.3390/genes12111731] [Reference Citation Analysis]
87 Sebayel MA, Ramirez C, Kizilisik AT, Geldhof G, Bhatti TJ, Abdullah A. Four-year experience with liver transplantation in Saudi Arabia. Transplant Proc 1998;30:3245-6. [PMID: 9838433 DOI: 10.1016/s0041-1345(98)01012-4] [Reference Citation Analysis]
88 Peyton A, Bhamidimarri KR. Hepatitis C treatment in liver transplant setting. Clin Liver Dis (Hoboken) 2015;5:145-9. [PMID: 31040972 DOI: 10.1002/cld.475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Li C, Candotti D, Allain JP. Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J Virol. 2001;75:12412-12420. [PMID: 11711631 DOI: 10.1128/JVI.75.24.12412-12420.2001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
90 Choudhary NS, Saigal S, Gautam D, Saraf N, Rastogi A, Goja S, Bhangui P, Soin AS. Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of Hepatitis C Recurrence After Living Donor Liver Transplantation: An Experience From India. J Clin Exp Hepatol 2018;8:121-4. [PMID: 29892173 DOI: 10.1016/j.jceh.2017.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
91 Joshi D, Agarwal K. Role of liver transplantation in human immunodeficiency virus positive patients. World J Gastroenterol 2015; 21(43): 12311-12321 [PMID: 26604639 DOI: 10.3748/wjg.v21.i43.12311] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
92 Vasuri F, Malvi D, Gruppioni E, Grigioni WF, D’Errico-Grigioni A. Histopathological evaluation of recurrent hepatitis C after liver transplantation: A review. World J Gastroenterol 2014; 20(11): 2810-2824 [PMID: 24659874 DOI: 10.3748/wjg.v20.i11.2810] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
93 Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem. World J Gastroenterol 2014; 20(32): 11095-11115 [PMID: 25170198 DOI: 10.3748/wjg.v20.i32.11095] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
94 Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, Farmer DG, Yersiz H, Danino N, Collisson E, Baquarizo A, Han SS, Saab S, Goldstein LI, Donovan JA, Esrason K, Busuttil RW. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-93; discussion 393-4. [PMID: 11524591 DOI: 10.1097/00000658-200109000-00012] [Cited by in Crossref: 197] [Cited by in F6Publishing: 179] [Article Influence: 9.4] [Reference Citation Analysis]
95 Yang BS, Liu LX, Yuan M, Hou YB, Li QT, Zhou S, Shi YX, Gao BL. Multiple imaging modality-guided radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma in special locations. Diagn Interv Radiol 2020;26:131-9. [PMID: 32071022 DOI: 10.5152/dir.2019.18540] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Anand AC. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation? J Clin Exp Hepatol. 2017;7:42-54. [PMID: 28348470 DOI: 10.1016/j.jceh.2017.01.116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
97 Ciria R, Pleguezuelo M, Khorsandi SE, Davila D, Suddle A, Vilca-Melendez H, Rufian S, de la Mata M, Briceño J, Cillero PL, Heaton N. Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol 2013; 5(5): 237-250 [PMID: 23717735 DOI: 10.4254/wjh.v5.i5.237] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
98 Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl. 2012;18:1053-1059. [PMID: 22706796 DOI: 10.1002/lt.23482] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
99 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
100 Khan R, Singal AK, Anand BS. Outcomes after liver transplantation for combined alcohol and hepatitis C virus infection. World J Gastroenterol 2014; 20(34): 11935-11938 [PMID: 25232228 DOI: 10.3748/wjg.v20.i34.11935] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Hughes MG Jr, Rosen HR. Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl 2009;15:1395-411. [PMID: 19877210 DOI: 10.1002/lt.21866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
102 Yokoyama S, Bartlett A, Dar FS, Heneghan M, O'Grady J, Rela M, Heaton N. Outcome of liver transplantation for haemophilia. HPB (Oxford) 2011;13:40-5. [PMID: 21159102 DOI: 10.1111/j.1477-2574.2010.00237.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
103 Bizollon T, Ducerf C, Trepo C, Mutimer D. Hepatitis C virus recurrence after liver transplantation. Gut 1999;44:575-8. [PMID: 10075968 DOI: 10.1136/gut.44.4.575] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 1.9] [Reference Citation Analysis]
104 Naik GS, Tyagi MG. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J Clin Exp Hepatol 2012;2:42-54. [PMID: 25755405 DOI: 10.1016/S0973-6883(12)60090-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
105 Layden JE, Cotler S, Brown KA, Lucey MR, Te HS, Eswaran S, Fimmel C, Layden TJ, Clark NM. Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation 2012;94:178-84. [PMID: 22743546 DOI: 10.1097/TP.0b013e318253f7fa] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
106 Tamè M, Buonfiglioli F, Del Gaudio M, Lisotti A, Cecinato P, Colecchia A, Azzaroli F, D’Errico A, Arena R, Calvanese C, Quarneti C, Ballardini G, Pinna AD, Mazzella G. Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. World J Gastroenterol 2013; 19(32): 5278-5285 [PMID: 23983430 DOI: 10.3748/wjg.v19.i32.5278] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
107 Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, Saab S, Han S, Durazo F, Weaver M, Cao C, Chen T, Lipshutz GS, Holt C, Gordon S, Gornbein J, Amersi F, Ghobrial RM. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg. 2005;241:905-16; discussion 916-8. [PMID: 15912040 DOI: 10.1097/01.sla.0000164077.77912.98] [Cited by in Crossref: 301] [Cited by in F6Publishing: 241] [Article Influence: 17.7] [Reference Citation Analysis]
108 Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci. 2004;49:38-41. [PMID: 14992432 DOI: 10.1023/b:ddas.0000011599.78222.9e] [Cited by in Crossref: 28] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
109 Schmidt SC, Bahra M, Bayraktar S, Berg T, Schmeding M, Pratschke J, Neuhaus P, Neumann U. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci. 2010;55:2063-2069. [PMID: 19798575 DOI: 10.1007/s10620-009-0982-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
110 Simmonds P. Clinical relevance of hepatitis C virus genotypes. Gut 1997;40:291-3. [PMID: 9135513 DOI: 10.1136/gut.40.3.291] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
111 Caremani M, Tacconi D, Giorni P, Lapini L, Corradini S, Giaccherini R. Clinical management of patients with recurrent viral hepatitis after liver transplantation. J Ultrasound 2007;10:46-52. [PMID: 23396377 DOI: 10.1016/j.jus.2007.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Firpi RJ, Dong H, Clark VC, Soldevila-Pico C, Morelli G, Cabrera R, Norkina O, Shuster JJ, Nelson DR, Liu C. CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int. 2013;33:72-78. [PMID: 23107586 DOI: 10.1111/liv.12013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
113 Kaibori M, Ha-Kawa SK, Uchida Y, Ishizaki M, Hijikawa T, Saito T, Imamura A, Hirohara J, Uemura Y, Tanaka K. Recurrent hepatitis C after living donor liver transplantation detected by Tc-99m GSA liver scintigraphy. Dig Dis Sci. 2006;51:2013-2017. [PMID: 16977504 DOI: 10.1007/s10620-006-9534-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
114 Dumortier J, Boillot O, Scoazec JY. Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: Past, present and future. World J Gastroenterol 2014; 20(32): 11069-11079 [PMID: 25170196 DOI: 10.3748/wjg.v20.i32.11069] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
115 Biggins SW, Trotter J, Gralla J, Burton JR, Bambha KM, Dodge J, Brocato M, Cheng L, McQueen M, Forman L. Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol. 2013;58:969-976. [PMID: 23333445 DOI: 10.1016/j.jhep.2012.12.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
116 Ahlenstiel G. The natural killer cell response to HCV infection. Immune Netw. 2013;13:168-176. [PMID: 24198741 DOI: 10.4110/in.2013.13.5.168] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
117 Kaxiras A, Yamamoto S, Söderdahl G, Wernerson A, Axelsson R, Ericzon BG. Cyclosporin A, but not tacrolimus, negatively affects the hepatic extraction fraction of hepatobiliary scintigraphy in liver transplant recipients. EJNMMI Res 2014;4:73. [PMID: 26116130 DOI: 10.1186/s13550-014-0073-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis 2019;21:e13047. [PMID: 30615227 DOI: 10.1111/tid.13047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
119 Zignego AL, Giannini C, Gragnani L, Piluso A, Fognani E. Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. J Transl Med. 2012;10:158. [PMID: 22863056 DOI: 10.1186/1479-5876-10-158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
120 Tan CK. Liver transplantation: late complications. Transplant Proc 2000;32:1517-8. [PMID: 11119814 DOI: 10.1016/s0041-1345(00)01333-6] [Reference Citation Analysis]
121 Schiano TD, Martin P. Management of HCV infection and liver transplantation. Int J Med Sci 2006;3:79-83. [PMID: 16614748 DOI: 10.7150/ijms.3.79] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
122 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
123 Singh N, Gayowski T, Wagener MM, Marino IR. Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. Eur J Clin Microbiol Infect Dis 1997;16:821-6. [PMID: 9447904 DOI: 10.1007/BF01700412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
124 Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxì A. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res 2014;6:303-10. [PMID: 24971024 DOI: 10.2147/CEOR.S62092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
125 Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, Markmann JF, Drazan KE, Holt C, Imagawa D. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg. 1999;229:824-831; discussion 831-833. [PMID: 10363896 DOI: 10.1097/00000658-199906000-00009] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 6.3] [Reference Citation Analysis]
126 Hori T, Onishi Y, Kamei H, Kurata N, Ishigami M, Ishizu Y, Ogura Y. Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol 2016;29:454-9. [PMID: 27708510 DOI: 10.20524/aog.2016.0069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
127 Mitchell O, Gurakar A. Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. J Clin Transl Hepatol. 2015;3:140-148. [PMID: 26357641 DOI: 10.14218/jcth.2015.00005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
128 Jeong SW, Choi Y, Kim JW. Management of viral hepatitis in liver transplant recipients. Clin Mol Hepatol. 2014;20:338-344. [PMID: 25548738 DOI: 10.3350/cmh.2014.20.4.338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
129 Sugawara Y, Tamura S, Kokudo N. Antiviral treatment for hepatitis C virus infection after liver transplantation. Hepat Res Treat 2010;2010:475746. [PMID: 21151523 DOI: 10.1155/2010/475746] [Cited by in F6Publishing: 1] [Reference Citation Analysis]